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Background—Longitudinal studies of the clinical high risk (CHR) syndrome for psychosis have
emphasized the conversion vs non-conversion distinction and thus far have not focused intensively
on classification among non-converters. The present study proposes a system for classifying CHR
outcomes over time when using the Structured Interview for Psychosis-risk Syndromes and
evaluates its validity.
Method—The system for classifying CHR outcomes is referred to as “current status specifiers,”
with “current” meaning over the month prior to the present evaluation and “specifiers” indicating
a set of labels and descriptions of the statuses. Specifiers for four current statuses are described:
progression, persistence, partial remission, and full remission. Data from the North American
Prodromal Longitudinal Study were employed to test convergent, discriminant, and predictive
validity of the current status distinctions.
Results—Validity analyses partly supported current status distinctions. Social and role
functioning were more impaired in progressive and persistent than in remitted patients, suggesting
a degree of convergent validity. Agreement between CHR current statuses and current statuses for
a different diagnostic construct (DSM-IV Major Depression) was poor, suggesting discriminant
validity. The proportion converting to psychosis within a year was significantly higher in cases
meeting progression criteria than in those meeting persistence criteria and tended to be higher than
in those meeting full remission criteria, consistent with a degree of predictive validity.
Discussion—CHR syndrome current status specifiers could offer a potentially valid and useful
description of current clinical status among non-converters. Study in additional samples is needed.
Keywords
psychosis; clinical high risk; risk syndrome; current status; course of illness
1. Introduction
A prodromal period before the onset of frank schizophrenia has been recognized for at least
a century (Bleuler, 1911; Klosterkotter et al., 2008), and over the past two decades a
growing body of work has sought to diagnose a prodromal syndrome prospectively (Fusar-
Poli et al., 2013). One approach has been to define clinical high risk (CHR) criteria, also
known as at-risk mental state or ultra-high risk or risk syndrome (Schultze-Lutter et al.,
2011) criteria. Two structured diagnostic interviews, the Comprehensive Assessment of At
Risk Mental States (CAARMS) (Yung et al., 2004) and the Structured Interview for
Psychosis-risk Syndromes (SIPS) (McGlashan et al., 2010) have demonstrated reliability
and validity (Addington et al., 2007; Fusar-Poli et al., 2012b; Woods et al., 2009; Woods et
al., 2010; Yung et al., 2008; Yung et al., 2005).
While CHR criteria consistently have been statistically significant predictors of conversion,
it has become more clear over the past decade that the majority of patients meeting the
criteria do not go on to become psychotic (Cannon et al., 2008; Fusar-Poli et al., 2012a;
Nelson et al., 2013; Ruhrmann et al., 2010). Some of the non-converting patients remain
symptomatic over time, and others become symptom-free (Addington et al., 2011). At
present, however, existing diagnostic criteria have paid relatively little attention to follow-up
classification.
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This paper proposes a new classification system for CHR patients when using the SIPS over
time. The system is based on diagnostic criteria that establish eligibility for classification
and specifiers of current status that may vary over follow-up. Data from the first phase of the
North American Prodrome Longitudinal Study (Addington et al., 2007) (NAPLS-1) are used
to evaluate the validity of the current status distinctions.
2. Methods
In the term “current status specifiers,” “current” refers to the month prior to the present
evaluation and “specifiers” to a set of labels and descriptions of possible statuses. Although
conversion to psychosis could also be considered a current status, the focus of the present
paper is not upon the existing SIPS definition of conversion but on new specifiers of current
status for patients who have not converted or who have not converted yet. The proposed
current status specifiers are influenced by the severity/psychosis/remission specifiers used
for affective disorder diagnoses (American Psychiatric Association, 1987, 1994, 2013) and
remission criteria proposed for schizophrenia (van Os et al., 2006).
2.1 Current status specifiers
The SIPS identifies three CHR syndromes: Attenuated Psychotic Symptoms Syndrome
(APSS), Brief Intermittent Psychosis Syndrome (BIPS), and Genetic Risk and Deterioration
(GRD), all originally articulated by the Melbourne group (Yung et al., 1996b). In previous
versions of the SIPS, criteria for each CHR syndrome required recent worsening, and each
was scored only as currently present vs not currently present. Different ways of not meeting
current worsening criteria (features present but no longer worsening, features no longer
present, features never present) were not distinguished.
For each CHR syndrome Figure 1 outlines criteria for four current status specifiers:
progression, persistence, partial remission, and full remission. The current status specifiers
may be applied to patients meeting syndromal diagnostic criteria, also in Figure 1. The
syndromal criteria and the current status specifiers are intended to be used together, at initial
evaluation and/or at any follow-up assessment. The syndromal diagnosis would apply across
course while the current status could vary (for example: APSS currently progressive, or
GRD currently in partial remission).
Figure 1 shows that for APSS and BIPS a CHR diagnosis depends on a history of at least
one positive symptom meeting severity, frequency, and attribution criteria. APSS or BIPS
progression requires that these criteria be met currently as well as recent worsening: these
APSS or BIPS progression criteria are identical to our previously proposed SIPS criteria for
APSS and BIPS current presence yes vs no. APSS or BIPS persistence are similar to APSS
or BIPS progression in requiring that syndromal criteria be met currently but differ in that
worsening criteria cannot. For APSS or BIPS partial remission two pathways were
considered appropriate, following the format for DSM affective disorders in partial
remission. For the first pathway, no positive symptom can meet severity and attribution
criteria, but for no longer than 6 months. For the second pathway, one or more positive
symptoms do currently meet severity and attribution criteria but not frequency criteria.
Patients meeting criteria for this second route could potentially remain in partial remission
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for an indefinite period of time. For APSS or BIPS full remission, no positive symptom has
met severity and attribution criteria for longer than 6 months. GRD syndromal and current
status criteria are based on indices of genetic risk and changes in global functioning. Criteria
for GRD progression differ slightly from our previous criteria for GRD current presence
(rationale in supplementary data).
When patients meet criteria for a current status for one CHR syndrome (e.g. GRD partial
remission) but also criteria for a different current status for another CHR syndrome (e.g.
APSS progression), the overall CHR syndrome current status is defined according to the rule
“progression trumps persistence trumps partial remission trumps full remission.” The
supplementary data include pages from SIPS 5.6 providing detail on how syndromal
assessments and current status assessments are scored.
2.2 Subjects
NAPLS-1 methods have been described in detail previously (Addington et al., 2007). All
subjects provided written informed consent, and protocols were approved by institutional
review boards at each site. Symptomatic subjects from three groups according to the earlier
classification (Woods et al., 2009) were eligible for the present analyses if all 5 SIPS
positive symptoms were rated for severity either at baseline, 6 months, and 12 months or at
12, 18, and 24 months. Figure 2 shows the flow diagram of eligible subjects and reasons for
ineligibility.
2.3 Classification
Eligible subjects were then classified at each timepoint based as closely as possible on the
current status specifier scheme shown in Figure 1. NAPLS-1 data, however, were not
collected prospectively to map onto this criterion set, and therefore certain criteria either
could not be applied or required estimation methods. Early versions of the SIPS did not
provide for symptom specific frequency ratings, and therefore symptom frequency data were
unavoidably missing for some cases. Simple exclusion of these cases would introduce bias
(supplementary data) and so was not the preferred option. To avoid such bias, we placed
symptomatic but missing frequency cases into a separate “Smf” category (see Figure 2). We
then made use of data from the symptomatic patients who did have frequency ratings (Table
S1) to estimate percentages for current status specifiers among the Smf group, as detailed in
the supplementary data.
Ratings of symptom causal attribution were not added to the SIPS until after NAPLS-1 data
collection ended, and thus these data were never collected and this requirement had to be
waived.
Progression for APSS and GRD at follow-up was assessed by direct comparison of ratings
to those from one year previously. Evaluation of BIPS progression criteria utilized fields in
the SIPS that asked whether positive symptoms had progressed to a 6 in the past 3 months.
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2.4 Validity
We investigated the validity of the current status specifiers in three analyses. A convergent
validity analysis asked whether social or role functioning differed across current status. The
social and role functioning variables (Cornblatt et al., 2007) did not contribute to the CHR
syndrome diagnosis or to the current status specifier definitions. A discriminant validity
analysis evaluated the degree to which CHR current status was independent from DSM-IV
current status specifiers for comorbid major depression. Among comorbidities in CHR
patients (Fusar-Poli et al., 2014; Rosen et al., 2006; Salokangas et al., 2012; Woods et al.,
2009), major depression is perhaps the most frequent and among the most severe and also is
described by established (American Psychiatric Association, 1994, 2013) current status
specifiers. Lastly, predictive validity analyses asked whether the rate of conversion to
psychosis during a 12-month interval differed by current status at interval start. We chose 12
months as the shortest interval whose outcome did not depend on unmeasured information,
such as positive symptom or GAF data before baseline. The starting points of each available
12-month interval were lined up to provide a “snapshot” of the 12-month conversion rate.
2.5 Effects of treatment on conversion or progression after remission
In the NAPLS-1 cohort, some patients received psychotropic medication or psychosocial
treatment, either clinically during naturalistic research follow-along or in prospective
research trials, as previously described (Cadenhead et al., 2010; Cannon et al., 2008; Walker
et al., 2009; Woods et al., 2013). We thus also investigated the extent to which cases
converting or meeting progression criteria after having achieved remission could potentially
be accounted for by discontinuation of treatment.
2.6 Statistical methods
Analyses were conducted using SPSS, version 19. Convergent validity analyses employed
one-way ANOVA, with post-hoc pairwise testing by Student’s t-test. Discriminant validity
analyses employed Cohen’s kappa. Predictive validity analyses utilized Fisher’s exact tests.
3. Results
3.1 Availability of data
The NAPLS-1 database contains 624 symptomatic nonpsychotic patients at baseline (Woods
et al., 2009). Of these, 435 (70%, see Figure 2) were classifiable according to Figure 1,
including 58 who met the criteria for Persistence at baseline. At one year, 172/435 were
classifiable (40%) and at two years, 44/172 (26%). The primary reason for inability to
classify at baseline was that the information collected did not permit identification of
whether CHR had ever been present before baseline. The primary reason at follow-up was
the absence of visits (Figure 2). Differences between the present sample and samples in
other reports on the NAPLS-1 cohort are discussed in the supplementary data.
3.2 Current status determinations for individual CHR syndromes
Table S2 shows the degree of overlap between current status specifiers for the three CHR
syndromes among visits that ended intervals in Figure 2. As in previous studies the large
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majority of patients met criteria for APSS. In the relatively few cases where more than one
syndrome was present, the current statuses agreed about 40% of the time, with the “trumps
rule” coming into play otherwise (supplementary data).
3.3 Validity
Convergent validity—Tables 1 and S3–4 show that social and role functioning both
differed across the spectrum of CHR current status specifiers. Pairwise findings were also
similar for social and role functioning. For patients with either progressive or persistent
status, functioning was significantly lower than for patients in either partial or full remission.
Functioning did not differ significantly between progression and persistence statuses or
between partial and full remission. Statistical power was <0.80 for partial vs full remission
(Table S3).
Discriminant validity—Table 2 shows how current status specifiers for CHR syndrome
overlapped with those for DSM-IV Major Depression. Sixty-two percent of cases in a
known CHR status did not meet criteria for a major depression diagnosis. If these patients
with no major depression diagnosis are not considered, along with the 39 in Table 2 whose
major depression was coded as status unspecified (296.20 or 296.30), Table 2 can be
collapsed into a 2x2 categorization: either in partial/full remission or not, for each syndrome.
Among unremitted CHR cases (n=105), depression was remitted in 58 (55%). Among
remitted CHR cases (n=18), depression was not remitted in 4 (22%). Kappa for agreement
was 0.10 (less than 0.40 poor (Fleiss, 1981)).
Predictive validity—Table 3 summarizes outcomes of CHR cases by current status at
interval start. These same data may be traced in Figure 2. The proportion converting to
psychosis was significantly higher in cases meeting progression criteria than in those
meeting persistence criteria at interval start and tended to be higher than in those meeting
full remission criteria (Table S5). Proportions converting in the other pairwise comparisons
did not differ, but statistical power was low (Table S5).
3.4 Effects of treatment on conversion or progression after remission
Table 3 shows that four remitted patients then converted or met criteria for progression over
the next year. These outcomes generally did not appear to be accounted for by
discontinuation of treatment. Treatment data were complete, and a medication or
psychosocial treatment present at remission was discontinued before conversion/progression
in only one of these cases.
4. Discussion
This report presents nomenclature and criteria for syndromal diagnosis and current status
assessment for clinical high risk (CHR) patients. Data from the NAPLS-1 dataset provide
partial support for the validity of the current status designations.
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4.1 Validity of the current status definitions
Taken together, the convergent, discriminant, and predictive validity analyses are supportive
of the validity of the CHR current status specifiers as defined in Figure 1. These data must
be interpreted cautiously, however, because neither the convergent validity nor the
predictive validity analyses fully distinguished each current status specifier from all others.
The criteria in Figure 1 will need to be applied to additional samples to evaluate validity
fully. Persistence was distinguished from progression in the predictive validity analyses
(conversion events in Table 3) but not in the convergent validity analysis of functioning
(Table 1). The low functioning scores for patients in a persistent CHR status suggest the
need for longer follow-up to determine the likelihood of functional improvement in this
group. Partial remission was not significantly distinguished from full remission in either
analysis, although numerically patients in full remission did show higher functioning scores
and lower conversion rates than those in partial remission. The discriminant validity analysis
in Table 2, which suggests substantial independence between the course of the CHR
syndrome and the course of comorbid major depression, speaks to the validity of the CHR
syndrome as a whole in addition to the validity of the current status specifiers.
4.2 Utility of current status specification
The definitions shown in Figure 1 improve upon the SIPS assessment of CHR syndrome in
three ways. First, the definitions address a previous limitation with the use of the SIPS.
Previously, patients with continuing but no longer progressive symptoms had to be classified
as “not currently CHR” whereas now they can be coded “CHR, currently persistent.” There
may be applications where the present classification could be used for baseline eligibility
determination; for example, recruitment of patients coded as “ CHR, currently in full
remission” could be useful as entry criteria for clinical trial designs investigating whether
treatments sustain remission. Second, the definitions address ambiguities with the use the
term “remission” of CHR syndrome over the past few years (Addington et al., 2011;
Schlosser et al., 2012; Simon et al., 2012; Simon and Umbricht, 2010; Velthorst et al., 2011;
Ziermans et al., 2011), wherein it has not always been clear whether patients with persistent
symptoms qualified as remitted (because they no longer met the previously articulated CHR
current presence criteria). Meta-analyses of remission rates (Simon et al., 2013) would be
facilitated by consistent definition. In addition, remission from the less common BIPS and
GRD syndromes has not previously been addressed in the literature to our knowledge. Third,
the current status specifiers provide a richer description of the nonconverting patients.
Future studies could determine whether treatments differentially alter rates of continued
progression, persistence, or remission as well as conversion rates, and ordinal regression
analyses incorporating current statuses may be statistically more powerful in detecting
treatment effects than analyses of dichotomous conversion vs non-conversion.
The present data suggest that most remissions are generally stable over the next year (Table
3); however, a few patients did not remain in remission but converted to psychosis or met
criteria for progression. Analyses of treatment data suggest that in at least some cases the
loss of sustained remission can be unrelated to discontinuation of previous treatment. These
observations are consistent with a previously recognized course pattern wherein the original
occurrence of progression can sometimes constitute an “outpost syndrome” (Yung and
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McGorry, 1996a) followed by remission and then later recurrence of illness. Future studies
should focus on the course of remitted patients and on predictors of sustaining remission.
4.3 Limitations
A number of limitations are recognized. The most important limitation is the relative paucity
of visits where patients could be classified in persistent, partial remission, or full remission
status, and especially the limited number of one-year intervals beginning with those statuses.
This limitation applies to the convergent validity analysis in Table 1 and particularly to the
predictive validity analyses in Table 3 and led to low statistical power in both analyses
(Tables S3 and S5). Larger samples are needed of patients in these current statuses. We
underscore that in retrofitting current status classifications to the NAPLS-1 data it was never
possible fully to apply the attribution criterion shown in Figure 1, since this criterion was not
added to the SIPS formally until after NAPLS-1 data collection ended. Site training in the
SIPS did include the understanding that attenuated positive symptoms due to another
disorder did not qualify for a CHR syndrome diagnosis, but there are no fields in the
NAPLS-1 dataset to document application of this criterion. Another limitation is that
symptom frequency ratings were often not present in the NAPLS-1 dataset, due to their
introduction into the SIPS with version 4.0 in 2003, while the sites’ collection of data
occurred between 1998 and 2005. For intervals classifiable at start that required frequency
ratings to apply Figure 1 criteria at interval end, the needed frequency ratings were missing
50% of the time (supplementary data). Consequently the follow-up proportions of
progression, persistence, and partial remission statuses in Table 3 had partly to be estimated.
It also should be emphasized that inter-rater reliability remains to be established.
Lastly, it is not yet clear for how long a diagnosis of CHR remains appropriate after full
remission has been achieved and continuously sustained. Future research may permit
recommendations for a definition of recovery or for use of a term such as “past history of a
CHR diagnosis.”
4.4 Implications
Current status distinctions (progression, persistence, partial remission, full remission) for
CHR patients appear to be valid and potentially useful. Their application to additional
samples may be warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Definitions for clinical high risk syndrome and current status specifiers when using the
SIPS.
SIPS--Structured Interview for Psychosis-risk Syndromes, APSS--Attenuated Psychotic
Symptoms Syndrome, BIPS--Brief Intermittent Psychosis Syndrome, GRD--Genetic Risk
and functional Decline, pos--positive, sx--symptoms, FHx--family history of, SPD--
schizotypal personality disorder, Hx--history of, GAF--Global Assessment of Functioning.
N.B. When a patient meets criteria for two or more specific CHR syndromes now meets
criteria for one at a higher level than another (e.g. both APSS progressive and GRD
persistent), the higher level current status is given as the overall CHR syndrome status. To
be explicit, “progression trumps persistence trumps partial remission trumps full remission.”
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Figure 2.
Subject flow diagram of NAPLS-1 sample in the present analysis.
Classifications shown at baseline with the Structured Interview for Psychosis-risk
Syndromes (SIPS) under the original classification scheme and for assessments as per the
present paper for syndroinal diagnosis and current status specification, at baseline, one year,
and two years.
CHR–clinical high risk. SPD–schizotypal personality disorder. PROG–progressive current
status; of CHR syndrome. No FU–no follow-up classification possible, no end–did not have
a study visit at the endpoint of the one-year interval, no mid–did not have a study visit at the
midpoint of the one-year interval, msg data–study visits occurred but severity data for one or
more positive symptoms were missing. PERS–persistent current status of CHR syndrome.
Unit–unknown CHR history, PSYCH–transitioned to frank psychosis. PART–partial
remission current status of CHR syndrome. FULL–fell remission current status of CHR
syndrome. Smf–currently symptomatic but cannot be classified as PROG vs PERS vs PART
due to missing symptom frequency data.
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